Skip to Main Content

K&L Gates Advises SoniVie in its Acquisition by Boston Scientific for US$600 Million

5 March 2025

Global law firm K&L Gates LLP advised SoniVie Ltd., a privately held medical device company, on its acquisition by Boston Scientific. The deal is valued at a total of up to US$600 million, with US$400 million paid upfront and up to $US200 million paid upon achievement of regulatory milestones. Boston Scientific anticipates the transaction to be completed in the first half of 2025, subject to customary closing conditions.

This is K&L Gates’ second sell-side transaction with Boston Scientific in the past year. The same deal team also guided NASDAQ-listed medical technology company Axonics in its US$3.7 billion sale, which was completed in late 2024.

The cross-office deal team was led by Orange County partners Michael Hedge and Jason Dreibelbis, with assistance from Orange County partners Mattias Luukkonen and Brian Novak, San Francisco partner Ali Nardali, Research Triangle Park partner Michael Hinckle, Chicago partners Mitch Weiss and Jake Trevick, Washington, D.C., partner Vishal Mehta, Seattle associate Henry Brockway, San Francisco associate Olivia Stitz, and Orange County associates Kailey Ashton and Corben Brooks.

K&L Gates’ Corporate practice is one of the most substantial in the legal industry, with hundreds of lawyers in offices on five continents providing clients with practical legal solutions in the structuring, financing, and completion of domestic, international, and cross-border transactions.

Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel